Mulitgene Assay Better Predictor of Survival than Conventional Staging
In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team, led by UCSF thoracic surgeons David M. Jablons, M.D. and Michael Mann, M.D., demonstrated that a 14-gene prognostic molecular assay better predicted the likelihood of death in early-stage lung cancer patients versus conventional staging guidelines. Johannes Kratz, M.D., a former surgical resident in the Thoracic Oncology Laboratory, helped spearhead the development of the assay and was lead author of a paper published in The Lancet discussing the results. John Minna, M.D.", Max L. Thomas Distinguished Chair in Molecular Pulmonary Oncology at UT Southwestern lauded the results, stating that the assay was "head and shoulders" above the rest and ready for "prime time" clinical use.
Related Links
New Lung Cancer Test Predicts Survival (by Jason Bardi - UCSF News Center)
Genetic Test for Early Stage Lung Cancer (Video Interview with Johannes Kratz, M.D.)
David Jablons Audio Interview with The Lancet
New Lung Cancer Assay Ready for Prime Time (Medscape Oncology News)